VA
IMCR icon

VR Adviser’s Immunocore IMCR Stock Holding History

VR Adviser’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-94,605
Closed -$4.44M – 32
2022
Q3 		$4.44M Buy
+94,605
New +$4.51M 0.69% 27

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser's IMCR Position: Q4 2022 in Review

VR Adviser sold out of Immunocore (IMCR) in Q4 2022, closing a stake of 94,605 shares — an estimated $4.44M sold.

VR Adviser first reported a position in IMCR in Q3 2022 and held it in 1 quarter. The position peaked at $4.44M in Q3 2022. 104 funds tracked by Wall St. Rank hold IMCR as of Q4 2022.

  • VR Adviser reported no remaining Immunocore position as of Q4 2022 after selling out during the quarter.
  • VR Adviser sold 94,605 Immunocore shares in Q4 2022, an estimated $4.44M.
  • VR Adviser first reported a position in Immunocore in Q3 2022 and held it in 1 quarter.
  • VR Adviser's Immunocore position peaked at $4.44M in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Immunocore as of Q4 2022.

Based on VR Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.